Affymetrix to obtain eBioscience Affymetrix.

With eBioscience, Affymetrix will increase its addressable markets with the addition of an industry-leading portfolio of cell-based and immunoassays. These services are a critical component of our customers’ workflow in our key target marketplaces of translational medicine, oncology, and immunology. We believe that these marketplaces represent a nearly $3 billion annual opportunity, which will place Affymetrix on a solid path to sustained growth and profitability.If the cells aren’t identical to the mom cell, they become tumor, Liu said. Regular cells employ a tightly regulated process to avoid aneuploidy, or the unequal distribution of chromosomes. Aneuploidy is certainly a hallmark of cancer. Related StoriesStudy shows uncommon HER2 missense mutations usually do not spread breasts cancer on the ownOvarian cancer sufferers with a history of oral contraceptive make use of have got better outcomesViralytics enters into clinical trial collaboration agreement with MSDA cell will proceed through two important procedures before it divides: It’ll create a second copy of its own DNA, and it shall create two centrosomes, or poles, which will act as magnets to attract the DNA to themselves.